Muciclar (Ambroxol Hydrochloride)

Ambroxol Hydrochloride stimulates serous glands in the airway epithelium, increasing the production of watery secretions and surfactant. This reduces the viscosity of mucus, enhances ciliary motion, and promotes mucociliary clearance, thereby facilitating the removal of mucus plugs from the respiratory tract.

The appropriate dose of Muciclar is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and response to therapy. Dosage regimens may vary, and the prescriber will provide specific instructions tailored to each individual.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the Muciclar product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Muciclar (Ambroxol) differs from agents such as N‑acetylcysteine by primarily stimulating serous secretion and surfactant production, whereas N‑acetylcysteine acts as a thiol‑reducing agent. Ambroxol often has a more favorable taste profile for inhalation and may be preferred when a rapid increase in mucus fluidity is desired.

Muciclar should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to extreme temperatures that could affect its stability.

Muciclar is intended for inhalation. The patient inhales the medication using a suitable nebulizer or inhalation device as directed by the prescriber. Proper technique ensures optimal delivery of the drug to the lower respiratory tract.

Serious adverse reactions, although rare, include severe allergic responses such as rash, urticaria, bronchospasm, respiratory distress, and anaphylactic shock. Immediate medical attention is required if any of these symptoms develop during treatment.

Muciclar is contraindicated in individuals with known hypersensitivity to Ambroxol Hydrochloride or any excipients in the formulation. Patients with uncontrolled severe bronchospasm should avoid use until the condition is stabilized, and it should be used with caution in those with significant renal or hepatic impairment.